Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA)...
Hence then, the article about biocity s eta selective antagonist sc0062 granted breakthrough therapy designation in china for diabetic kidney disease with albuminuria was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria )
Also on site :
- BTS Dominates YouTube’s Global, U.S. Charts
- Quest Global est reconnue comme un leader dans le rapport ISG Provider Lens® 2025 Report for Manufacturing Industry Services and Solutions
- NYT Mini Crossword Answers, Hints for Thursday, April 2, 2026